What percentage of cancers recur after achieving remission (complete response)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Approximately 30%–40% of patients with localized cancer and 60%–80% with metastatic disease at presentation experience recurrence. The percentage of cancers that return after remission varies widely depending on the type of cancer, stage at diagnosis, treatment received, and individual patient factors 1. Some cancers have much higher recurrence rates, while others have very low recurrence rates. Recurrence risk is typically highest in the first 2-5 years after treatment, though some cancers can return decades later. Factors that increase recurrence risk include advanced stage at diagnosis, aggressive tumor characteristics, inadequate treatment response, and certain genetic mutations. Some key points to consider include:

  • The presence of solitary metastases, time to first relapse, and complete resectability of the disease at first recurrence have been reported to be the most important prognostic indicators for improved survival 1.
  • Patients who initially presented with widespread disease are more likely to relapse at distant sites, whereas those individuals who presented with localized disease are more likely to develop local relapse 1.
  • Regular follow-up appointments with oncologists are essential for monitoring potential recurrence, typically scheduled every 3-6 months initially, then annually after 5 years 1.
  • Cancer recurrence happens because some cancer cells may survive initial treatment despite achieving clinical remission, remaining dormant before eventually growing again. It's worth noting that the recurrence rates can vary significantly depending on the specific type of cancer, with some cancers like ovarian cancer having much higher recurrence rates (70-90%), while others like early-stage thyroid cancer have very low recurrence rates (less than 5%) 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Cancer Recurrence Rates

  • The percentage of cancers that return after remission varies depending on the type and stage of cancer, as well as the treatment received 2, 3.
  • According to a study published in the Irish Journal of Medical Science, 25-30% of breast cancer patients develop disease recurrence and die from the disease dissemination 2.
  • Another study published in The New England Journal of Medicine found that the five-year actuarial rates of local recurrence were 7.3% and 4.3% for patients who received standard radiotherapy and additional radiation, respectively 3.

Factors Influencing Recurrence

  • Several factors can influence the risk of cancer recurrence, including the type and stage of cancer, treatment received, and patient characteristics such as age and tumor biology 2, 4.
  • A study published in the British Journal of Cancer found that metastatic relapse can occur months to decades after initial diagnosis and treatment, and that the biology of metastasis is not yet fully understood 4.
  • Other factors that can influence recurrence include the presence of certain molecular subtypes, such as HER2-positive or triple-negative breast cancer, and the use of targeted therapies 5, 6.

Treatment and Recurrence

  • Treatment options for cancer can also influence the risk of recurrence, with some treatments being more effective than others in preventing recurrence 3, 5.
  • A study published in the European Journal of Cancer Care found that the cost per life-year gained from chemotherapy and targeted therapy can vary significantly depending on the treatment indication and stage of cancer 5.
  • Another study published in Current Oncology found that targeted therapies, such as CDK 4/6 inhibitors and PI3K inhibitors, can improve outcomes for patients with hormone receptor-positive and HER2-negative breast cancer 6.

Related Questions

What is the recommended treatment for patients with a local recurrence of estrogen receptor-positive (ER+) breast cancer, specifically regarding radiation therapy?
What are the indications for breast radiotherapy?
What are the indications for radiotherapy (radiation therapy) in breast cancer?
What are the indications for radiotherapy (radiation therapy) in breast cancer?
What are the treatment options for CD4+ (Cluster of Differentiation 4 positive) breast cancer?
What laboratory tests are recommended for Rheumatoid Arthritis (RA) diagnosis and what values are significant?
What is the recommended treatment for a 45-year-old gentleman with chronic bloody diarrhea, abdominal pain, fecal incontinence, and significant weight loss, diagnosed with inflammatory bowel disease (IBD) unresponsive to steroids, mesalazine (Mesalamine), Cipro (Ciprofloxacin) and metronidazole, with laboratory results showing hypoproteinemia, normal liver function tests, and negative tests for hepatitis B, HIV, CMV, and tuberculosis (TB)?
What is the most likely diagnosis for a 62-year-old woman with cirrhosis due to Hepatitis C (HCV), a 2.5-centimeter encapsulated solid lesion with arterial phase hyperenhancement and delayed venous washout on multi-phase Computed Tomography (CT), and an elevated serum alpha-fetoprotein (AFP) level of 19?
What medication reduces the risk of recurrent Primary Biliary Cholangitis (PBC) in patients undergoing liver transplantation: Azathioprine (AZA), Ursodeoxycholic Acid (UDCA), Prednisone, or Ursodiol (Ursodeoxycholic Acid)?
What can cause a woman to have consecutive pregnancies with fetal hydrops (hydrops fetalis)?
What are the recommended colonoscopy screening guidelines for a 16-year-old girl with a confirmed MLH1 mutation (DNA mismatch repair gene) and a family history of adenocarcinoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.